^
    CANCER:

    Liposarcoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    XPO1 inhibitor
    selinexor
    1
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    2
    Alkylating agent, DNA inhibitor
    trabectedin
    3
    PD1 inhibitor
    pembrolizumab
    RAIN-32
    		4
    MDM2 inhibitor
    APG-115
    MK-8242
    HDM201
    5
    MDM2-p53 antagonist
    BI 907828
    6
    LSD1 inhibitor
    SP2577
    7
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    8
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate
    9
    PARP inhibitor
    PARP inhibitor
    10
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor, MDM2 inhibitor
    erdafitinib + RG7388
    11
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    12
    β-catenin inhibitor, Microtubule stabilizer, Tubulin polymerization promoter, CBP inhibitor, Microtubule inhibitor
    docetaxel + eribulin mesylate
    13
    HDAC inhibitor
    romidepsin
    No biomarker
    CALB1 deletion
    CALB1 underexpression
    MDM2 amplification
    GRM1 overexpression
    MDM2 overexpression
    TP53 wild-type
    PIK3CA mutation
    CDK4 amplification
    RB1 expression
    FUS-DDIT3 translocation
    MCM4 overexpression
    MDM2 amplification + TP53 wild-type
    FGFR1 overexpression
    FGFR4 overexpression
    MDM2 amplification + CDK4 amplification
    PIK3CA mutation + TERT promoter mutation